
Wilson Werber Bryan MD
Neuromuscular Medicine, Neurophysiology
Physician
Join to View Full Profile
10903 New Hampshire AvenueWO71 - 5230Silver Spring, MD 20993
Phone+1 240-402-8266
Dr. Bryan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Tufts Medical CenterFellowship, Neuromuscular Medicine (Neurology), 1986 - 1987
- University of Texas Southwestern Medical CenterResidency, Neurology, 1983 - 1986
- Emory University School of MedicineInternship, Internal Medicine, 1982 - 1983
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1982
Certifications & Licensure
- MD State Medical License 2001 - 2024
- TX State Medical License 1985 - 2023
- DC State Medical License 2002 - 2016
- VA State Medical License 2002 - 2012
- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 2 citationsCross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project.Matthew Foster, Yonatan Negash, Leslie Eberhardt, Wilson W Bryan, Kimberly Schultz
Molecular Therapy Oncolytics. 2022-12-15 - 35 citationsFDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.Poornima Sharma, Bindu Kanapuru, Bindu George, Xue Lin, Zhenzhen Xu
Clinical Cancer Research. 2022-05-02 - 8 citationsAssociation of immune globulin intravenous and thromboembolic adverse events.Mikhail V Ovanesov, Mikhail Menis, Dorothy E. Scott, Richard A. Forshee, Steven A. Anderson
American Journal of Hematology. 2017-01-01
Press Mentions
- FDA Advisory Committee Unanimous in Support of Bluebird Bio’s Two Gene TherapiesJune 10th, 2022
- US Stem Cell Clinics Boomed While FDA Paused CrackdownSeptember 30th, 2021
- FDA Ramping up 'Enforcement Activities' Against Unapproved Stem Cell TherapiesJune 10th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: